PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Kathrin Klein	09/15/2011
Stephan Riedmaier	09/19/2011
Ulrich Zanger	09/19/2011

RECEIVING PARTY DATA

Name:	Robert Bosch GmbH
Street Address:	Postfach 30 02 20
City:	Stuttgart
State/Country:	GERMANY
Postal Code:	70442

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	13260508

CORRESPONDENCE DATA

Fax Number: (317)638-2139 Phone: 317-638-2922

Email: docketing@maginot.com

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

via US Mail.

Correspondent Name: Maginot, Moore & Beck Address Line 1: 111 Monument Circle

Address Line 2: Suite 3250

Address Line 4: Indianapolis, INDIANA 46204-5109

ATTORNEY DOCKET NUMBER:	2178-0029
NAME OF SUBMITTER:	Paul J. Maginot

Total Attachments: 5

PATENT REEL: 027542 FRAME: 0259 340 00 H

source=R328213_2178-0029_Assignment#page1.tif source=R328213_2178-0029_Assignment#page2.tif source=R328213_2178-0029_Assignment#page3.tif source=R328213_2178-0029_Assignment#page4.tif source=R328213_2178-0029_Assignment#page5.tif

> PATENT REEL: 027542 FRAME: 0260

ASSIGNMENT

Pursuant to our obligation to Robert Bosch GmbH (hereinafter referred to as "Assignee"), a German corporation having a mailing address at:

> Postfach 30 02 20 D-70442 Stuttgart **GERMANY**

and for other valuable and sufficient consideration, receipt whereof is hereby acknowledged, we:

> Kathrin Klein Ludwigstr. 82 70197 Stuttgart **GERMANY**

Stephan Riedmaier 70197 Stuttgart **GERMANY**

Jamebergerste, 6, SR 13. 9. 2011 87770 Oberschenegs

Ulrich Zanger Stettiner Sr. 29 70825 Korntal **GERMANY**

confirm our obligation to and hereby sell, assign and convey, unto Assignee, its successors and assigns, except as set forth below, our entire right, title and interest -

(1) in and to an invention entitled "Method for Determining the Predisposition of a Patient to Changed Biotransformation and to the Development of Undesired Drug Effects in a Treatment of the Patient with Atorvastatin" for which we have executed a United States patent application on even date herewith, said United States application being assigned U.S. Serial No. 13/240,508 filed on ______ (We hereby authorize Assignee to insert the serial number and filing date in the preceding blanks) and which is disclosed in Patent Cooperation Treaty Application No. PCT/EP2010/052245, filed on February 23, 2010;

> **PATENT** REEL: 027542 FRAME: 0261

(2) in and to said United States patent application, in and to all other patent

applications (including divisional, continuation, continuation-in-part, §111(b) provisional,

§111(a), reissue applications, and international patent applications designating the United

States) based upon said invention, and in and to the patent or patents to be granted thereon,

including reissues thereof, if any, to the full end of the term or terms for which said patent or

patents may be granted; and

(3) in and to all patent applications on said invention now or hereafter filed in

countries foreign to the United States of America, including patent applications filed under

the Patent Cooperation Treaty, the European Patent Convention or any other international

treaty, and including the right to claim priority of said United States application, and in and to

any and all patents granted on said applications to the full end of the terms for which said

patents may be granted.

We hereby agree that we will, upon demand of Assignee, its successors or

assigns, and without further consideration to us, execute any and all papers that may be

necessary, or deemed by Assignee, its successors or assigns, to be necessary, to a complete

fulfillment of the intent and purposes of this Assignment, it being understood that any

expense incident to the execution of such papers shall be paid by Assignee, its successors and

assigns, and not by us.

Page 2 of 5

PATENT REEL: 027542 FRAME: 0262

allui Veri Date 15.09.2011

Stephan Riedmaier

Hlrich Zanger

Date X /)

Page 5 of 5